Trial
NCT05327803
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AN2 Therapeutics, Inc
Collaborators
—
Condition
MAC Lung Disease
Intervention
Epetraborole
Why stopped
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-10